Company Filing History:
Years Active: 2013
Title: Susanne Miehe: Innovator in Pharmacology
Introduction
Susanne Miehe is a prominent inventor based in Frankfurt am Main, Germany. She has made significant contributions to the field of pharmacology, particularly in the study of TRPC ion channels. Her work focuses on the development of novel medicines targeting these channels, which play crucial roles in various physiological functions.
Latest Patents
Susanne Miehe holds a patent for the "Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC7 ion channels." This invention provides a pharmacological tool compound that allows researchers to study TRPC ion channels due to its discriminating inhibition of TRPC subfamilies. Norgestimate has been shown to selectively inhibit TRPC3, TRPC6, and TRPC7, addressing the need for a better understanding of these channels in human tissues.
Career Highlights
Miehe is currently associated with Sanofi, a leading global healthcare company. Her work at Sanofi has allowed her to contribute to innovative research and development in the pharmaceutical industry. With her expertise, she has been able to advance the understanding of ion channels and their implications in medicine.
Collaborations
Throughout her career, Susanne Miehe has collaborated with notable colleagues, including Heinz-Werner Kleemann and Carsten Struebing. These collaborations have further enriched her research and contributed to the advancement of knowledge in her field.
Conclusion
Susanne Miehe's innovative work in pharmacology, particularly her patent on norgestimate, highlights her significant contributions to the understanding of TRPC ion channels. Her career at Sanofi and collaborations with esteemed colleagues underscore her impact on the pharmaceutical industry.